rs276174848

Variant names:

• chr13-32326153-AT-A
• rs276174848
• NM_000059.4:c.475+4delT

Variant summary

Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM2 PP5_Very_Strong

The NM_000059.4(BRCA2):​c.475+4delT variant causes a splice region, intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000000686 in 1,456,676 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★).

• Frequency:
  • Genomes: not found (cov: 33)
  • Exomes 𝑓: 6.9e-7 (0 hom.)
• Consequence: BRCA2 NM_000059.4 splice_region, intron
• Clinical Significance: Pathogenic/Likely pathogenic criteria provided, multiple submitters, no conflicts P:7 U:1
• Conservation: PhyloP100: 1.32

Genes affected

BRCA2 (HGNC:1101): (BRCA2 DNA repair associated) Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintenance of genome stability, specifically the homologous recombination pathway for double-strand DNA repair. The largest exon in both genes is exon 11, which harbors the most important and frequent mutations in breast cancer patients. The BRCA2 gene was found on chromosome 13q12.3 in human. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele. [provided by RefSeq, May 2020]

ACMG classification

Verdict is Pathogenic. Variant got 10 ACMG points.

• PM2: Very rare variant in population databases, with high coverage
• PP5: Variant 13-32326153-AT-A is Pathogenic according to our data. Variant chr13-32326153-AT-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 37921.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.

Transcripts

RefSeq

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	MANE	Protein	UniProt
BRCA2	NM_000059.4	c.475+4delT		splice_region_variant, intron_variant	Intron 5 of 26	ENST00000380152.8	NP_000050.3

Ensembl

Gene	Transcript	HGVSc	HGVSp	Effect	Exon rank	TSL	MANE	Protein	Appris	UniProt
BRCA2	ENST00000380152.8	c.475+4delT		splice_region_variant, intron_variant	Intron 5 of 26	5	NM_000059.4	ENSP00000369497.3
BRCA2	ENST00000530893.7	c.106+4delT		splice_region_variant, intron_variant	Intron 5 of 26	1		ENSP00000499438.2
BRCA2	ENST00000614259.2	n.475+4delT		splice_region_variant, intron_variant	Intron 4 of 25	2		ENSP00000506251.1

Frequencies

GnomAD3 genomes Cov.: 33

GnomAD4 exome AF: 6.86e-7 AC: 1 AN: 1456676 Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0 AN XY: 724920

Gnomad4 AFR exome AF: 0.00

Gnomad4 AMR exome AF: 0.00

Gnomad4 ASJ exome AF: 0.00

Gnomad4 EAS exome AF: 0.00

Gnomad4 SAS exome AF: 0.00

Gnomad4 FIN exome AF: 0.00

Gnomad4 NFE exome AF: 9.02e-7

Gnomad4 OTH exome AF: 0.00

GnomAD4 genome Cov.: 33

ClinVar

Significance: Pathogenic/Likely pathogenic

Submissions summary: Pathogenic:7 Uncertain:1

Revision: criteria provided, multiple submitters, no conflicts

Submissions by phenotype

Breast-ovarian cancer, familial, susceptibility to, 2 Pathogenic:2 Uncertain:1

Jan 31, 2022

MGZ Medical Genetics Center

Significance: Likely pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

- -

Oct 18, 2011

Sharing Clinical Reports Project (SCRP)

Significance: Likely pathogenic

Review Status: no assertion criteria provided

Collection Method: clinical testing

- -

Dec 23, 2003

Breast Cancer Information Core (BIC) (BRCA2)

Significance: Uncertain significance

Review Status: no assertion criteria provided

Collection Method: clinical testing

- -

Hereditary cancer-predisposing syndrome Pathogenic:2

Mar 23, 2020

Color Diagnostics, LLC DBA Color Health

Significance: Likely pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This variant causes deletion of a T in intron 5 of the BRCA2 gene. Functional studies have shown that this variant resulted in exon 5 skipping and premature truncation (PMID: 32133419). This variant has been reported in individuals affected with breast cancer (PMID: 32133419, 25948282). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Based on the available evidence, this variant is classified as Likely Pathogenic. -

Dec 26, 2023

Ambry Genetics

Significance: Likely pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

The c.475+4delT intronic variant, located in intron 4 of the BRCA2 gene, results from a deletion of one nucleotide within intron 4 of the BRCA2 gene. This nucleotide position is well conserved in available vertebrate species. This alteration was identified in a Polish individual with a family history and/or personal history of early onset breast and/or ovarian cancer (Kluska A et al. BMC Med Genomics, 2015 May;8:19). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). In silico splice site analysis predicts that this alteration may weaken the native splice donor site. RNA studies have demonstrated this alteration results in abnormal splicing in the set of samples tested (Ambry internal data; Wai HA et al. Genet Med 2020 06;22(6):1005-1014). Based on the majority of available evidence to date, this variant is likely to be pathogenic. -

Hereditary breast ovarian cancer syndrome Pathogenic:2

Jan 03, 2023

Women's Health and Genetics/Laboratory Corporation of America, LabCorp

Significance: Likely pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

Variant summary: BRCA2 c.475+4delT alters a non-conserved nucleotide located close to a canonical splice site and therefore it could affect mRNA splicing, leading to a significantly altered protein sequence. Several computational tools predict a significant impact on normal splicing: three predict the variant weakens a 5' donor site. Publications utilizing patient derived blood RNA samples reported experimental evidence, confirming that this variant affects splicing, resulting in exon 5 skipping with a premature truncation at the protein level (Landrith_2020, Wai_2020). The variant was absent in 251000 control chromosomes (gnomAD). The variant, c.475+4delT, has been reported in the literature in multiple individuals affected with Hereditary Breast and Ovarian Cancer Syndrome (Kluska_2015, Landrith_2020). These data indicate that the variant is likely associated with disease. Five other clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 and classified as Likely pathogenic (n=4) and VUS (n=1). Based on the evidence outlined above, the variant was classified as likely pathogenic. -

Dec 15, 2024

Labcorp Genetics (formerly Invitae), Labcorp

Significance: Pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

This sequence change falls in intron 5 of the BRCA2 gene. It does not directly change the encoded amino acid sequence of the BRCA2 protein. RNA analysis indicates that this variant induces altered splicing and may result in an absent or altered protein product. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with breast cancer, prostate cancer (PMID: 25948282, 32133419). ClinVar contains an entry for this variant (Variation ID: 37921). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant results in skipping of exon 5, and produces a non-functional protein and/or introduces a premature termination codon (PMID: 32133419; internal data). For these reasons, this variant has been classified as Pathogenic. -

not provided Pathogenic:1

May 27, 2022

GeneDx

Significance: Likely pathogenic

Review Status: criteria provided, single submitter

Collection Method: clinical testing

Non-canonical splice variant demonstrated to result in out-of-frame exon 5 skipping (Landrith 2020, Wai 2020); Observed in individuals with familial breast/ovarian cancer (Kluska 2015); Not observed at significant frequency in large population cohorts (gnomAD); Also known as 703+4del; This variant is associated with the following publications: (PMID: 32133419, 31131967, 27060066, 32123317, 25948282) -

Computational scores

Source: dbNSFP v4.3

Splicing

Name	Calibrated prediction	Score	Prediction
SpliceAI score (max)		0.42		Details are displayed if max score is > 0.2
DS_DL_spliceai		0.42		Position offset: -3

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Other links and lift over

dbSNP: rs276174848; hg19: chr13-32900290;